Skip to main content

Patient Selection for Phrenic Nerve Stimulation with remedē®

The remedē System is FDA approved for the treatment of moderate-to-severe CSA in adult patients1 with:

  • No requirement to have tried and failed other therapies for CSA
  • No upper limit of Apnea Hypopnea Index (AHI)
  • No upper limit of patient Body Mass Index (BMI)

Appropriate candidates for the remedē System may have events
other than central apneas noted during the sleep study

Patients for remedē therapy should have moderate-to-severe sleep apnea with AHI ≥ 15

In the remedē Pivotal Trial, patients had more central apneas than obstructive apneas2

remedē Patient Selection Pathway Example